NVX-CoV2373 Vaccine to Target Corona, Not Protein, Experiment Starts in Australia

Australian scientists are now preparing to beat Corona with the flu vaccine. Its trial on humans has started in the state of Victoria. The vaccine is named NVX-CoV2373 and is made by the American company Novavax.

It is being said that this is the first trial of a corona vaccine in the entire Southern Hemisphere and an attempt is being made to understand how it affects coronaviruses.

4 points: how vaccine will work

Immune cells will attack spike proteins

According to the company's researchers, the vaccine will put pressure on the immune system's cells to fight the virus. The special thing about the vaccine being used in the trial is that it will attack the spina protein of corona instead of targeting the whole virus. This part of the virus is largely responsible for the infection.

Treating protein fragments as viruses

Researchers say that due to the vaccine, the protein of the corona will break into small pieces, called nano particles. Immune cells of the body, considering these particles as small viruses, will activate and catch them.

Matrix-M will send signals to immune cells

According to the researchers, the vaccine will contain nano particles named Matrix-M, they will give signals to immune cells as soon as they see danger in the body. This will repeatedly alert and activate cells so that they can eliminate protein fragments.

Influenza vaccine based

The vaccine being tested on the corona is based on the influenza virus, known as nanoflu. It was built by the Novavax company. In October last year, its third phase trial was conducted at 2650 volunteers.